Clinical Trial Update: Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of AR-42 (pan-DAC inhibitor) with pazopanib in advanced renal cell carcinoma and soft tissue sarcoma was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Soft Tissue Sarcoma

Drugs mentioned

• AR-42 (AR-42)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Renal Cell Carcinoma, Soft Tissue Sarcoma | Phase 1 | Status: TERMINATED | Results posted: 2019-10-24